Inactive Instrument

Clinical Laserthermia Systems AB Stock Swiss Exchange

Equities

CLSR.B

SE0002756130

Advanced Medical Equipment & Technology

End-of-day quote Swiss Exchange
- SEK - Intraday chart for Clinical Laserthermia Systems AB

Financials

Sales 2023 8.27M 785K 1.08M Sales 2024 * 39M 3.7M 5.1M Capitalization 49.52M 4.7M 6.47M
Net income 2023 -79M -7.5M -10.33M Net income 2024 * -54M -5.13M -7.06M EV / Sales 2023 20.5 x
Net cash position 2023 14.88M 1.41M 1.94M Net cash position 2024 * 29.7M 2.82M 3.88M EV / Sales 2024 * 0.51 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 3.26%
More Fundamentals * Assessed data
Clinical Laserthermia Systems to Raise SEK59 Million via Rights Issue MT
Clinical Laserthermia Systems AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Clinical Laserthermia Systems AB Enters into an Exclusive Distribution Agreement with MTEC Company CI
Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory MT
Clinical Laserthermia Systems AB Presents Initial Data from the Investigator Initiated Trial at Radboud University Medical Center Using the CLS Transberg System CI
Clinical Laserthermia Systems Receives Second Order from the National Institutes of Health Clinical Center in the US for its TRANBERG Thermal Therapy System Accessories CI
Clinical Laserthermia Systems AB Announces Two Patients with Localized Prostate Cancer Have Been Safely Treated with the Tranberg Thermal Therapy System At the San Luigi Gonzaga University Hospital in Turin, Italy CI
Clinical Laserthermia Systems AB's Subsidiary CLS Americas Signs Agreement with ROSE Urology for Treatment of Prostate Cancer Patients with TRANBERG Thermal Therapy System CI
Clinical Laserthermia Systems Names Interim CFO MT
Clinical Laserthermia Systems AB Announces CFO Changes CI
Clinical Laserthermia Systems AB Announces Publication of Preclinical Assessment of A Non-Cooled MR Thermometry-Based Neurosurgical Laser Therapy System CI
Clinical Laserthermia Systems AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Clinical Laserthermia Systems AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Clinical Laserthermia Systems Gains Underwriting Commitments for Warrant Series Exercise MT
Clinical Laserthermia Systems Files Patent Extension, Expansion for Non-cooled Laser Applicators MT
More news
Managers TitleAgeSince
Chief Executive Officer - -
Founder 75 06-03-08
Chief Tech/Sci/R&D Officer - 21-12-31
Members of the board TitleAgeSince
Director/Board Member 69 09-12-31
Chairman 74 10-12-31
Founder 75 06-03-08
More insiders
Clinical Laserthermia Systems AB is a Sweden-based company active in the medical equipment industry. The Company develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). imILT method can be used for all tumors in solid organ and the potential market is considerable. Examples of tumors which are suitable for treatment are those found in liver, breast, lung, prostate, kidney, pancreas and thyroid. Clinical Laserthermia Systems AB's treatment system consists of two main parts: a mobile laser device and a sterile patient unit for single use. The Company's product is intended for medical professionals within surgical oncology or interventional radiology within oncology. In April 2014, the Company announced the establishment of a subsidiary in the United States.
Calendar
More about the company